Status:
COMPLETED
Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
Lead Sponsor:
Titan Pharmaceuticals
Conditions:
Opioid Dependence
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Prob...
Eligibility Criteria
Inclusion
- Voluntarily provide written informed consent prior to conduct of any study-related procedures
- Completed 24 weeks of treatment in PRO-805
- Deemed appropriate for entry into this extension study by the Investigator
- Females of childbearing potential and fertile males must use a reliable means of contraception
Exclusion
- Presence of aspartate aminotransferase (AST) levels ≥ 3 X upper limit of normal and/or alanine aminotransferase (ALT) levels ≥ 3 X upper limit of normal and/or total bilirubin ≥ 1.5 X upper limit of normal and/or creatinine ≥ 1.5 X upper limit of normal
- Current diagnosis of chronic pain requiring opioids for treatment
- Pregnant or lactating females
- Current use of agents metabolized through cytochrome P450 3A4 (CYP 3A4) such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir)
- Current anti-coagulant therapy (such as warfarin) or an INR \> 1.2
- Current use of benzodiazepines other than physician prescribed use
- Significant medical or psychiatric symptoms, cognitive impairment, or other factors which in the opinion of the Investigator, would preclude compliance with the protocol, patient safety, adequate cooperation in the study, or obtaining informed consent
- Concurrent medical conditions (such as severe respiratory insufficiency) that may prevent the patient from safely participating in study; and/or any pending legal action that could prohibit participation and/or compliance in study
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00630201
Start Date
October 1 2007
End Date
February 1 2009
Last Update
December 31 2018
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
David Geffen School of Medicine at UCLA
Los Angeles, California, United States
2
Synergy Clinical Research Center
National City, California, United States, 91950
3
Amit Vijapura, MD
Jacksonville, Florida, United States, 32256
4
Fidelity Clinical Research, Inc.
Lauderhill, Florida, United States